GlassScriptPhysician profile
Rajeev Saini
NPI 1447259403
$1,621.57
in general payments reported to CMS, 2019-2025
22 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $321 · 2022: $204 · 2023: $175 · 2024: $465 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $264.54 | 2021-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $261.12 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Medtronic, INC. | $194.60 | 2021-2022 | |
| Abbvie INC. | $122.39 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $105.69 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $84.69 | 2023-2024 | Repatha, Otezla, Prolia |
| Mylan Specialty L.P. | $76.49 | 2024 | Yupelri |
| Glaxosmithkline, LLC. | $69.10 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $61.96 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $58.78 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.36 | 2024-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $32.71 | 2024-2025 | Freestyle Libre 2 |
| Corcept Therapeutics | $31.93 | 2025 | Korlym |
| Pfizer INC. | $31.81 | 2023-2024 | |
| Exact Sciences Corporation | $31.36 | 2024-2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $26.41 | 2025 | Inspire |
| Ars Pharmaceuticals Operations, INC. | $20.59 | 2025 | Neffy |
| Axsome Therapeutics, INC. | $20.11 | 2024 | Auvelity |
| Shield Therapeutics INC | $18.78 | 2025 | |
| Merck Sharp & Dohme LLC | $18.68 | 2024 | Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $18.08 | 2022 | |
| Bardy Diagnostics, INC. | $14.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.